EET intervention on Wnt1, NOV, and HO-1 signaling prevents obesity-induced cardiomyopathy in obese mice

Jian Cao, Shailendra P. Singh, John A. McClung, Gregory Joseph, Luca Vanella, Ignazio Barbagallo, Houli Jiang, J R Falck, Michael Arad, Joseph I. Shapiro, Nader G. Abraham

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

We have previously reported that epoxyeicosatrienoic acid (EET) has multiple beneficial effects on vascular function; in addition to its antiapoptotic action, it increases insulin sensitivity and inhibits inflammation. To uncover the signaling mechanisms by which EET reduces cardiomyopathy, we hypothesized that EET infusion might ameliorate obesity-induced cardiomyopathy by improving heme oxygenase (HO)-1, Wnt1, thermogenic gene levels, and mitochondrial integrity in cardiac tissues and improved pericardial fat phenotype. EET reduced levels of fasting blood glucose and proinflammatory adipokines, including nephroblastoma overexpressed (NOV) signaling, while increasing echocardiographic fractional shortening and O2 consumption. Of interest, we also noted a marked improvement in mitochondrial integrity, thermogenic genes, and Wnt 1 and HO-1 signaling mechanisms. Knockout of peroxisome proliferator-activated receptor-γ coactivator-1β (PGC-1β) in EET-treated mice resulted in a reversal of these beneficial effects including a decrease in myocardial Wnt1 and HO-1 expression and an increase in NOV. To further elucidate the effects of EET on pericardial adipose tissues, we observed EET treatment increases in adiponectin, PGC-1β, phospho-AMP-activated protein kinase, insulin receptor phosphorylation, and thermogenic genes, resulting in a “browning” pericardial adipose phenotype under high-fat diets. Collectively, these experiments demonstrate that an EET agonist increased Wnt1 and HO-1 signaling while decreasing NOV pathways and the progression of cardiomyopathy. Furthermore, this report presents a portal into potential therapeutic approaches for the treatment of heart failure and metabolic syndrome. NEW & NOTEWORTHY The mechanism by which EET acts on obesity-induced cardiomyopathy is unknown. Here, we describe a previously unrecognized function of EET infusion that inhibits nephroblastoma overexpressed (NOV) levels and activates Wnt1, hence identifying NOV inhibition and enhanced Wnt1 expression as novel pharmacological targets for the prevention and treatment of cardiomyopathy and heart failure. Listen to this article’s corresponding podcast at http://ajpheart. physiology.org/content/early/2017/05/31/ajpheart.00093.2017.

Original languageEnglish (US)
Pages (from-to)H368-H380
JournalAmerican Journal of Physiology - Heart and Circulatory Physiology
Volume313
Issue number2
DOIs
StatePublished - Aug 11 2017

Fingerprint

Obese Mice
Heme Oxygenase-1
Wilms Tumor
Cardiomyopathies
Obesity
Acids
Treatment Failure
Heart Failure
Webcasts
Phenotype
Peroxisome Proliferator-Activated Receptors
AMP-Activated Protein Kinases
Adipokines
Mitochondrial Genes
Adiponectin
Insulin Receptor
High Fat Diet
Genes
Blood Vessels
Insulin Resistance

Keywords

  • Cardiomyopathy
  • Heme oxygenase-1
  • Hypertension
  • Metabolic syndrome
  • Myocardial biology
  • Nephroblastoma overexpressed
  • Oxidative stress

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this

EET intervention on Wnt1, NOV, and HO-1 signaling prevents obesity-induced cardiomyopathy in obese mice. / Cao, Jian; Singh, Shailendra P.; McClung, John A.; Joseph, Gregory; Vanella, Luca; Barbagallo, Ignazio; Jiang, Houli; Falck, J R; Arad, Michael; Shapiro, Joseph I.; Abraham, Nader G.

In: American Journal of Physiology - Heart and Circulatory Physiology, Vol. 313, No. 2, 11.08.2017, p. H368-H380.

Research output: Contribution to journalArticle

Cao, J, Singh, SP, McClung, JA, Joseph, G, Vanella, L, Barbagallo, I, Jiang, H, Falck, JR, Arad, M, Shapiro, JI & Abraham, NG 2017, 'EET intervention on Wnt1, NOV, and HO-1 signaling prevents obesity-induced cardiomyopathy in obese mice', American Journal of Physiology - Heart and Circulatory Physiology, vol. 313, no. 2, pp. H368-H380. https://doi.org/10.1152/ajpheart.00093.2017
Cao, Jian ; Singh, Shailendra P. ; McClung, John A. ; Joseph, Gregory ; Vanella, Luca ; Barbagallo, Ignazio ; Jiang, Houli ; Falck, J R ; Arad, Michael ; Shapiro, Joseph I. ; Abraham, Nader G. / EET intervention on Wnt1, NOV, and HO-1 signaling prevents obesity-induced cardiomyopathy in obese mice. In: American Journal of Physiology - Heart and Circulatory Physiology. 2017 ; Vol. 313, No. 2. pp. H368-H380.
@article{fea7bbd99ac546d1a678de9363e3d0df,
title = "EET intervention on Wnt1, NOV, and HO-1 signaling prevents obesity-induced cardiomyopathy in obese mice",
abstract = "We have previously reported that epoxyeicosatrienoic acid (EET) has multiple beneficial effects on vascular function; in addition to its antiapoptotic action, it increases insulin sensitivity and inhibits inflammation. To uncover the signaling mechanisms by which EET reduces cardiomyopathy, we hypothesized that EET infusion might ameliorate obesity-induced cardiomyopathy by improving heme oxygenase (HO)-1, Wnt1, thermogenic gene levels, and mitochondrial integrity in cardiac tissues and improved pericardial fat phenotype. EET reduced levels of fasting blood glucose and proinflammatory adipokines, including nephroblastoma overexpressed (NOV) signaling, while increasing echocardiographic fractional shortening and O2 consumption. Of interest, we also noted a marked improvement in mitochondrial integrity, thermogenic genes, and Wnt 1 and HO-1 signaling mechanisms. Knockout of peroxisome proliferator-activated receptor-γ coactivator-1β (PGC-1β) in EET-treated mice resulted in a reversal of these beneficial effects including a decrease in myocardial Wnt1 and HO-1 expression and an increase in NOV. To further elucidate the effects of EET on pericardial adipose tissues, we observed EET treatment increases in adiponectin, PGC-1β, phospho-AMP-activated protein kinase, insulin receptor phosphorylation, and thermogenic genes, resulting in a “browning” pericardial adipose phenotype under high-fat diets. Collectively, these experiments demonstrate that an EET agonist increased Wnt1 and HO-1 signaling while decreasing NOV pathways and the progression of cardiomyopathy. Furthermore, this report presents a portal into potential therapeutic approaches for the treatment of heart failure and metabolic syndrome. NEW & NOTEWORTHY The mechanism by which EET acts on obesity-induced cardiomyopathy is unknown. Here, we describe a previously unrecognized function of EET infusion that inhibits nephroblastoma overexpressed (NOV) levels and activates Wnt1, hence identifying NOV inhibition and enhanced Wnt1 expression as novel pharmacological targets for the prevention and treatment of cardiomyopathy and heart failure. Listen to this article’s corresponding podcast at http://ajpheart. physiology.org/content/early/2017/05/31/ajpheart.00093.2017.",
keywords = "Cardiomyopathy, Heme oxygenase-1, Hypertension, Metabolic syndrome, Myocardial biology, Nephroblastoma overexpressed, Oxidative stress",
author = "Jian Cao and Singh, {Shailendra P.} and McClung, {John A.} and Gregory Joseph and Luca Vanella and Ignazio Barbagallo and Houli Jiang and Falck, {J R} and Michael Arad and Shapiro, {Joseph I.} and Abraham, {Nader G.}",
year = "2017",
month = "8",
day = "11",
doi = "10.1152/ajpheart.00093.2017",
language = "English (US)",
volume = "313",
pages = "H368--H380",
journal = "American Journal of Physiology - Heart and Circulatory Physiology",
issn = "0363-6135",
publisher = "American Physiological Society",
number = "2",

}

TY - JOUR

T1 - EET intervention on Wnt1, NOV, and HO-1 signaling prevents obesity-induced cardiomyopathy in obese mice

AU - Cao, Jian

AU - Singh, Shailendra P.

AU - McClung, John A.

AU - Joseph, Gregory

AU - Vanella, Luca

AU - Barbagallo, Ignazio

AU - Jiang, Houli

AU - Falck, J R

AU - Arad, Michael

AU - Shapiro, Joseph I.

AU - Abraham, Nader G.

PY - 2017/8/11

Y1 - 2017/8/11

N2 - We have previously reported that epoxyeicosatrienoic acid (EET) has multiple beneficial effects on vascular function; in addition to its antiapoptotic action, it increases insulin sensitivity and inhibits inflammation. To uncover the signaling mechanisms by which EET reduces cardiomyopathy, we hypothesized that EET infusion might ameliorate obesity-induced cardiomyopathy by improving heme oxygenase (HO)-1, Wnt1, thermogenic gene levels, and mitochondrial integrity in cardiac tissues and improved pericardial fat phenotype. EET reduced levels of fasting blood glucose and proinflammatory adipokines, including nephroblastoma overexpressed (NOV) signaling, while increasing echocardiographic fractional shortening and O2 consumption. Of interest, we also noted a marked improvement in mitochondrial integrity, thermogenic genes, and Wnt 1 and HO-1 signaling mechanisms. Knockout of peroxisome proliferator-activated receptor-γ coactivator-1β (PGC-1β) in EET-treated mice resulted in a reversal of these beneficial effects including a decrease in myocardial Wnt1 and HO-1 expression and an increase in NOV. To further elucidate the effects of EET on pericardial adipose tissues, we observed EET treatment increases in adiponectin, PGC-1β, phospho-AMP-activated protein kinase, insulin receptor phosphorylation, and thermogenic genes, resulting in a “browning” pericardial adipose phenotype under high-fat diets. Collectively, these experiments demonstrate that an EET agonist increased Wnt1 and HO-1 signaling while decreasing NOV pathways and the progression of cardiomyopathy. Furthermore, this report presents a portal into potential therapeutic approaches for the treatment of heart failure and metabolic syndrome. NEW & NOTEWORTHY The mechanism by which EET acts on obesity-induced cardiomyopathy is unknown. Here, we describe a previously unrecognized function of EET infusion that inhibits nephroblastoma overexpressed (NOV) levels and activates Wnt1, hence identifying NOV inhibition and enhanced Wnt1 expression as novel pharmacological targets for the prevention and treatment of cardiomyopathy and heart failure. Listen to this article’s corresponding podcast at http://ajpheart. physiology.org/content/early/2017/05/31/ajpheart.00093.2017.

AB - We have previously reported that epoxyeicosatrienoic acid (EET) has multiple beneficial effects on vascular function; in addition to its antiapoptotic action, it increases insulin sensitivity and inhibits inflammation. To uncover the signaling mechanisms by which EET reduces cardiomyopathy, we hypothesized that EET infusion might ameliorate obesity-induced cardiomyopathy by improving heme oxygenase (HO)-1, Wnt1, thermogenic gene levels, and mitochondrial integrity in cardiac tissues and improved pericardial fat phenotype. EET reduced levels of fasting blood glucose and proinflammatory adipokines, including nephroblastoma overexpressed (NOV) signaling, while increasing echocardiographic fractional shortening and O2 consumption. Of interest, we also noted a marked improvement in mitochondrial integrity, thermogenic genes, and Wnt 1 and HO-1 signaling mechanisms. Knockout of peroxisome proliferator-activated receptor-γ coactivator-1β (PGC-1β) in EET-treated mice resulted in a reversal of these beneficial effects including a decrease in myocardial Wnt1 and HO-1 expression and an increase in NOV. To further elucidate the effects of EET on pericardial adipose tissues, we observed EET treatment increases in adiponectin, PGC-1β, phospho-AMP-activated protein kinase, insulin receptor phosphorylation, and thermogenic genes, resulting in a “browning” pericardial adipose phenotype under high-fat diets. Collectively, these experiments demonstrate that an EET agonist increased Wnt1 and HO-1 signaling while decreasing NOV pathways and the progression of cardiomyopathy. Furthermore, this report presents a portal into potential therapeutic approaches for the treatment of heart failure and metabolic syndrome. NEW & NOTEWORTHY The mechanism by which EET acts on obesity-induced cardiomyopathy is unknown. Here, we describe a previously unrecognized function of EET infusion that inhibits nephroblastoma overexpressed (NOV) levels and activates Wnt1, hence identifying NOV inhibition and enhanced Wnt1 expression as novel pharmacological targets for the prevention and treatment of cardiomyopathy and heart failure. Listen to this article’s corresponding podcast at http://ajpheart. physiology.org/content/early/2017/05/31/ajpheart.00093.2017.

KW - Cardiomyopathy

KW - Heme oxygenase-1

KW - Hypertension

KW - Metabolic syndrome

KW - Myocardial biology

KW - Nephroblastoma overexpressed

KW - Oxidative stress

UR - http://www.scopus.com/inward/record.url?scp=85027266278&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027266278&partnerID=8YFLogxK

U2 - 10.1152/ajpheart.00093.2017

DO - 10.1152/ajpheart.00093.2017

M3 - Article

C2 - 28576832

AN - SCOPUS:85027266278

VL - 313

SP - H368-H380

JO - American Journal of Physiology - Heart and Circulatory Physiology

JF - American Journal of Physiology - Heart and Circulatory Physiology

SN - 0363-6135

IS - 2

ER -